All Outputs (2)

Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia (2021)
Journal Article
Naylor-Adamson, L., Chacko, A., Booth, Z., Caserta, S., Jarvis, J., Khan, S., …Arman, M. (2021). Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia. Frontiers in immunology, 12, Article 766272. https://doi.org/10.3389/fimmu.2021.766272

Bacterial infections are a major cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), and infection risk increases in patients treated with the Bruton’s tyrosine kinase (Btk) inhibitor, ibrutinib. Btk and related kinases (like Tec)... Read More about Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia.

A feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): Study protocol (2021)
Journal Article
Northgraves, M., Cohen, J., Allgar, V., Currow, D., Hart, S., Hird, K., Hodge, A., Johnson, M., Mason, S., Swan, F., & Hutchinson, A. (2021). A feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): Study protocol. ERJ Open Research, 7(1), Article 00955-2020. https://doi.org/10.1183/23120541.00955-2020

Introduction: Chronic breathlessness, persistent and disabling despite optimal treatment of underlying causes, is a prevalent and frightening symptom and is associated with many emergency presentations and admission to hospital. Breathlessness manage... Read More about A feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): Study protocol.